163 related articles for article (PubMed ID: 12895195)
1. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
Renders L; Haas CS; Liebelt J; Oberbarnscheidt M; Schöcklmann HO; Kunzendorf U
Br J Clin Pharmacol; 2003 Aug; 56(2):214-9. PubMed ID: 12895195
[TBL] [Abstract][Full Text] [Related]
2. Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.
Renders L; Czock D; Schöcklmann H; Kunzendorf U
Int J Clin Pharmacol Ther; 2003 Nov; 41(11):499-503. PubMed ID: 14620947
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
4. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
[TBL] [Abstract][Full Text] [Related]
5. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
6. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.
Renton KW; Crocker JF; McLellan H; Acott PD
Eur J Clin Pharmacol; 2004 Aug; 60(6):421-6. PubMed ID: 15232662
[TBL] [Abstract][Full Text] [Related]
8. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
Mück W; Park S; Jäger W; Voith B; Wandel E; Galle PR; Schwarting A
Int J Clin Pharmacol Ther; 2001 May; 39(5):192-8. PubMed ID: 11380064
[TBL] [Abstract][Full Text] [Related]
10. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
11. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
13. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus/cerivastatin interaction study in liver transplant recipients.
Mück W; Neal DA; Boix O; Voith B; Hasan R; Alexander GJ
Br J Clin Pharmacol; 2001 Aug; 52(2):213-5. PubMed ID: 11488782
[No Abstract] [Full Text] [Related]
19. Effect of itraconazole on cerivastatin pharmacokinetics.
Kantola T; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
[TBL] [Abstract][Full Text] [Related]
20. The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.
Campagne O; Mager DE; Brazeau D; Venuto RC; Tornatore KM
Br J Clin Pharmacol; 2019 Mar; 85(3):516-529. PubMed ID: 30414331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
